Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances in the development of covalent inhibitors
Hyunsoo Kim, Yoon Soo Hwang, Mingi Kim, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 7, pp. 1037-1045
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168
A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations
Elma Mons, Sander Roet, Robbert Q. Kim, et al.
Current Protocols (2022) Vol. 2, Iss. 6
Open Access | Times Cited: 68
Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development
Fangjiao Huang, Xiaoli Han, Xiaohui Xiao, et al.
Molecules (2022) Vol. 27, Iss. 22, pp. 7728-7728
Open Access | Times Cited: 58
Catalyst-free late-stage functionalization to assemble α-acyloxyenamide electrophiles for selectively profiling conserved lysine residues
Yuanyuan Zhao, Duan Kang, Youlong Fan, et al.
Communications Chemistry (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 8
The expanding repertoire of covalent warheads for drug discovery
Namrashee V. Mehta, Mariam S. Degani
Drug Discovery Today (2023) Vol. 28, Iss. 12, pp. 103799-103799
Closed Access | Times Cited: 20
Restoring susceptibility to β-lactam antibiotics in methicillin-resistant Staphylococcus aureus
Van Trung Nguyen, Biruk Tesfaye Birhanu, Vega Miguel-Ruano, et al.
Nature Chemical Biology (2024)
Closed Access | Times Cited: 6
Activity-based protein profiling guided new target identification of quinazoline derivatives for expediting bactericide discovery
Jiao Meng, Ling Zhang, Xinxin Tuo, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 6
CovPDB: a high-resolution coverage of the covalent protein–ligand interactome
Mingjie Gao, Aurélien F. A. Moumbock, Ammar Qaseem, et al.
Nucleic Acids Research (2021) Vol. 50, Iss. D1, pp. D445-D450
Open Access | Times Cited: 35
Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions
Ahmed M. Shawky, Faisal A. Almalki, Hayat Ali Alzahrani, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116704-116704
Closed Access | Times Cited: 5
Development of a Highly Selective Ferroptosis Inducer Targeting GPX4 with 2-Ethynylthiazole-4-carboxamide as Electrophilic Warhead
Shi‐Hong Gu, Guanyu Yang, Huiting Bian, et al.
Journal of Medicinal Chemistry (2025) Vol. 68, Iss. 3, pp. 3309-3323
Closed Access
Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization
Veronica Di Sarno, Gianluigi Lauro, Simona Musella, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113863-113863
Open Access | Times Cited: 30
Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
Chau Ngo, William Fried, Saba R. Aliyari, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12237-12248
Open Access | Times Cited: 12
AI-driven covalent drug design strategies targeting main protease (m pro ) against SARS-CoV-2: structural insights and molecular mechanisms
Mohammad Hossein Haghir Ebrahim Abadi, Abdulrahman Ghasemlou, Fatemeh Bayani, et al.
Journal of Biomolecular Structure and Dynamics (2024), pp. 1-29
Closed Access | Times Cited: 4
Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
Design of ROS-Triggered Sesquiterpene Lactone SC Prodrugs as TrxR1 Covalent Inhibitors for the Treatment of Non-Small Cell Lung Cancer
Hui Ren, Yujue Wang, Xinye Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
DNA-encoded Libraries with Covalent Warheads
Sixiu Liu, Rui Jin, Zhiqiang Duan, et al.
Royal Society of Chemistry eBooks (2025), pp. 119-133
Closed Access
Monitoring of Propiolamide-Mediated Molecular Crosstalk between Ferroptosis and Apoptosis by Raman Spectroscopy
Jiaheng Yu, Song Li, Guangyang Xu, et al.
Analytical Chemistry (2025)
Closed Access
Synthesis, screening and validation of cysteine-reactive fragments as chikungunya virus protease inhibitors
Junming He, Henry Illingworth, Sven Ullrich, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130176-130176
Open Access
Covalent inhibitors possessing autophagy-modulating capabilities: charting novel avenues in drug design and discovery
Yutong Wang, Shiyu Luo, Hongbao Sun, et al.
Drug Discovery Today (2025), pp. 104347-104347
Closed Access
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection
Lei Tian, Taotao Qiang, Xiuding Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 264, pp. 115979-115979
Closed Access | Times Cited: 9
Multiscale calculations reveal new insights into the reaction mechanism between KRASG12C and α, β-unsaturated carbonyl of covalent inhibitors
Xiao Yan, Chuan‐Hua Qu, Qin Li, et al.
Computational and Structural Biotechnology Journal (2024) Vol. 23, pp. 1408-1417
Open Access | Times Cited: 3
New techniques and strategies in drug discovery (2020–2024 update)
Qijie Gong, Jian Song, Yihui Song, et al.
Chinese Chemical Letters (2024), pp. 110456-110456
Closed Access | Times Cited: 3
Cyclopropenone, Cyclopropeniminium Ion, and Cyclopropenethione as Novel Electrophilic Warheads for Potential Target Discovery of Triple-Negative Breast Cancer
Shumin Lv, Fang Xu, Youlong Fan, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2851-2864
Closed Access | Times Cited: 8
Covalent fragment approaches targeting non-cysteine residues
Noémi Csorba, Péter Ábrányi‐Balogh, György M. Keserü
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 802-816
Open Access | Times Cited: 7
DNA encoded peptide library for SARS-CoV-2 3CL protease covalent inhibitor discovery and profiling
Yuyu Xing, Huiya Zhang, Yanhui Wang, et al.
RSC Chemical Biology (2024) Vol. 5, Iss. 7, pp. 691-702
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top